Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00982449 | 124I-FIAU Imaging in EBV and KSHV Associated Cancers | completed | N/A | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT02795013 | Genetic Study of Families With High Frequency of Hodgkin Lymphoma | completed | — | 27 | St. Jude Children's Research HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT03664323 | Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma | completed | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00754286 | A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer | completed | N/A | 132 | Albert Einstein College of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | completed | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01877005 | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma(HIJAK) | completed | Phase 2 | 33 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 22, 2018 | clinicaltrials |
| NCT00484874 | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00026208 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | completed | Phase 2 | 76 | Stanford UniversityOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity(BREVITY) | completed | Phase 2 | 38 | University of BirminghamOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00385788 | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01393717 | Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma | completed | Phase 2 | 57 | City of Hope Medical CenterOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01056679 | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients(AVD-Rev) | completed | Phase 1 | 30 | University of CologneOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT03469921 | Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016(HEMAJA) | completed | — | 602 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01820117 | Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation | completed | — | 416 | St. Jude Children's Research HospitalOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT01534078 | Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01969435 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT02244021 | BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV | completed | Phase 2 | 13 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT02247869 | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | completed | Phase 2 | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients(HD0801) | completed | Phase 2 / Phase 3 | 520 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00667615 | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT02057445 | 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma | completed | Phase 1 | 1 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT02378337 | Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality(pet-ct) | completed | — | 335 | Hospital Sao RafaelOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01078350 | Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy | completed | — | 93 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00540007 | Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 80 | Washington University School of MedicineOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02885038 | Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies(TCP) | completed | — | 1,101 | Etablissement Français du SangOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT01833884 | Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic(CYTOKINES-LH) | completed | N/A | 50 | Centre Henri BecquerelOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00924131 | Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial | completed | — | 157 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00388349 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | completed | Phase 2 | 146 | Stanford UniversityOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02099266 | Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | completed | N/A | 15 | University of Kansas Medical CenterOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2018source: clinicaltrials